Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (615,000)	$ (252,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	61,000	64,000
Amortization of debt issuance costs	98,000	94,000
Allowance for doubtful accounts	3,000	2,000
Provision for slow moving and obsolete inventory	14,000	2,000
Share-based payment expense	11,000	33,000
Changes in:
Accounts receivable	(202,000)	32,000
Inventory	209,000	116,000
Prepaid expenses and other current assets	51,000	96,000
Accounts payable	85,000	2,000
Accrued expenses and other current liabilities	114,000	11,000
Wages payable	0	(42,000)
Net cash (used in) / provided by operating activities	(171,000)	158,000
Cash flows from investing activities:
Patent application costs	(21,000)	(20,000)
Purchase of property, plant and equipment	0	(44,000)
Net cash used in investing activities	(21,000)	(64,000)
Cash flows from financing activities:
Proceeds from / (payments on) debt financing	66,000	(41,000)
Proceeds from lines of credit	3,194,000	4,729,000
Payments on lines of credit	(3,045,000)	(4,788,000)
Net cash provided by / (used in) financing activities	215,000	(100,000)
Net (decrease in) / increase in cash and cash equivalents	23,000	(6,000)
Cash and cash equivalents - beginning of period	36,000	156,000
Cash and cash equivalents - end of period	59,000	150,000
Supplemental disclosures of cash flow information
Consulting expense prepaid with restricted stock	25,000	50,000
Debt issuance cost paid with restricted stock	18,000	0
Director Fee paid with restricted stock	3,000	0
Patent application costs	21,000	20,000
Cash paid during period for interest	118,000	110,000
Cash paid / ( received) during period for taxes	$ 2,000	$ (1,000)